Advertisement
Advertisement
PHVS
Pharvaris N.V. Ordinary Shares
34.91
USDSponsored
+0.46
+1.34%
Aug 07, 15:59 UTC -4
Closed
After-Market
35.06
+0.16
+0.44%
PHVS Earnings Reports
Positive Surprise Ratio
PHVS beat 13 of 22 last estimates.
59%
Next Report
Date of Next Report
Aug 19, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.66
Implied change from Q1 26 (Revenue/ EPS)
--
/+11.86%
Implied change from Q2 25 (Revenue/ EPS)
--
/-20.48%
Pharvaris N.V. Ordinary Shares earnings per share and revenue
On May 12, 2026, PHVS reported earnings of -0.59 USD per share (EPS) for Q1 26, beating the estimate of -0.72 USD, resulting in a 18.76% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -6.80% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 9 analysts forecast an EPS of -0.66 USD, with revenue projected to reach -- USD, implying an increase of 11.86% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
BioMarin Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.70
Actual
$1.20
Surprise
+71.04%
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Prime Medicine, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.24
Surprise
+8.57%
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
FAQ
What were Pharvaris N.V. Ordinary Shares's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Pharvaris N.V. Ordinary Shares reported EPS of -$0.59, beating estimates by 18.76%, and revenue of $0.00, 0% as expectations.
How did the market react to Pharvaris N.V. Ordinary Shares's Q1 2026 earnings?
The stock price moved down -6.8%, changed from $32.94 before the earnings release to $30.70 the day after.
When is Pharvaris N.V. Ordinary Shares expected to report next?
The next earning report is scheduled for Aug 19, 2026.
What are the forecasts for Pharvaris N.V. Ordinary Shares's next earnings report?
Based on 9
analysts, Pharvaris N.V. Ordinary Shares is expected to report EPS of -$0.66 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement